作为抑郁症治疗反应的可能调节器的皮层下大脑体积的多基因评分
Vincenzo Oliva1,2,3,4, Alfonso Martone1, Giuseppe Fanelli1,5
1Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.
Neuroscience applied
|July 14, 2025
概括
对大脑体积的多基因评分没有预测主要抑郁症 (MDD) 治疗不响应. 初步发现表明尾状体积多基因分数与非缓解之间的潜在联系,需要进一步调查.
科学领域:
- 神经科学是一个神经科学.
- 精神病学是一个精神病学.
- 遗传学 是一个遗传学.
背景情况:
- 大型抑郁症 (MDD) 通常表现为治疗反应不佳.
- 大脑结构测量和遗传因素被探索为治疗结果的预测因素.
- 识别预测因素对于MDD个性化治疗策略至关重要.
研究的目的:
- 调查七个皮质下大脑体积的多基因分数 (PGS) 与MDD治疗不响应/不缓解之间的关联.
- 评估PGS在预测重大抑郁症治疗结果方面的潜力.
- 探索对MDD治疗耐药性的遗传贡献.
主要方法:
- 利用了来自五项临床研究的3637名MDD患者的数据.
- 预计皮层下大脑体积的PGS (海马体,体核,杏仁体,尾状核等) 使用PRS-CS-自动.
- 进行了PGS和治疗非反应/非缓解之间的后勤回归的元分析,调整为共变量.
主要成果:
- 在Bonferroni校正后,在皮层下大脑体积的PGS和MDD治疗不响应之间没有发现显著的关联.
- 在尾状体积PGS和非缓解之间观察到初步关联 (p=0.036),受较大样本的影响.
- 敏感性分析表明,初步发现依赖于特定的数据集,未达到统计意义值.
结论:
- 目前对皮质下大脑体积的多基因评分不能可靠地预测MDD的治疗结果.
- 与尾状体积的初步关联要求使用更大的样本大小进行进一步研究.
- 未来的研究旨在增强PGS在MDD治疗中的精密精神病学的预测能力.
相关概念视频
Human Genetics
732
Human genetics provides a profound framework for understanding the interplay between genetic predispositions and human psychology. At the heart of this discipline lies the study of how genes influence physical traits, behaviors, and susceptibility to diseases. Each person carries a unique genetic code that subtly or significantly shapes their psychological and behavioral landscape.
The complex relationship between genetics and psychology is observable through common biological components such...
The complex relationship between genetics and psychology is observable through common biological components such...
732
Depressive Disorders: Etiology
172
Depressive disorders result from a complex interplay of biological, psychological, and sociocultural factors, each contributing uniquely to the development and persistence of the condition. Understanding these factors provides critical insight into the multifaceted nature of depression.
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
172
Antidepressant Drugs: MAOIs and Other Agents
372
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
372
Depressive Disorders: MDD and Dysthymia
222
Depressive disorders are a group of mental health conditions characterized by pervasive feelings of sadness, diminished pleasure in life, and a significant impact on daily functioning. These conditions are most prevalent in individuals during their 30s and affect women at twice the rate of men. Contrary to popular belief, younger individuals are generally more susceptible to these disorders than older adults. Two key types of depressive disorders include Major Depressive Disorder (MDD) and...
222
Factors Affecting Drug Response: Overview
2.4K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
2.4K
Brain Imaging
318
Brain imaging technologies provide critical insights into both the structure and function of the human brain, enabling medical professionals and researchers to diagnose, study, and treat neurological disorders or psychiatric disorders more effectively.
These technologies include computerized axial tomography (CAT or CT scans), positron-emission tomography (PET scans), magnetic resonance imaging (MRI), functional magnetic resonance imaging (fMRI), and Transcranial Magnetic...
These technologies include computerized axial tomography (CAT or CT scans), positron-emission tomography (PET scans), magnetic resonance imaging (MRI), functional magnetic resonance imaging (fMRI), and Transcranial Magnetic...
318


